InVivo Therapeutics Holdings Corporation – NASDAQ:NVIV

InVivo Therapeutics Holdings stock price today

$0.231
-0.08
-27.97%
Financial Health
0
1
2
3
4
5
6
7
8
9

InVivo Therapeutics Holdings stock price monthly change

-58.65%
month

InVivo Therapeutics Holdings stock price quarterly change

-57.20%
quarter

InVivo Therapeutics Holdings stock price yearly change

-85.44%
year

InVivo Therapeutics Holdings key metrics

Market Cap
 995.91K
Enterprise value
 N/A
P/E
 -0.15
EV/Sales
 N/A
EV/EBITDA
 1.39
Price/Sales
 N/A
Price/Book
 0.10
PEG ratio
 -0.01
EPS
 -3.7
Revenue
 N/A
EBITDA
 -9.37M
Income
 -8.98M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

InVivo Therapeutics Holdings stock price history

InVivo Therapeutics Holdings stock forecast

InVivo Therapeutics Holdings financial statements

Profit Margin

InVivo Therapeutics Holdings Corporation (NASDAQ:NVIV): Profit margin
Dec 2022 0 -2.17M
Mar 2023 0 -2.17M
Jun 2023 0 -1.93M
Sep 2023 0 -2.69M
NVIV income statement history

Debt to Assets

InVivo Therapeutics Holdings Corporation (NASDAQ:NVIV): Debt to assets
Dec 2022 18822000 3.07M 16.34%
Mar 2023 15652000 2.17M 13.9%
Jun 2023 13334000 1.75M 13.18%
Sep 2023 9584000 666K 6.95%
NVIV balance sheet history

Cash Flow

InVivo Therapeutics Holdings Corporation (NASDAQ:NVIV): Cash Flow
Dec 2022 -2.19M -17K 7.96M
Mar 2023 -3.20M 2K 0
Jun 2023 -2.45M 22K 0
Sep 2023 -2.28M 43K 0
NVIV cash flow history

InVivo Therapeutics Holdings alternative data

InVivo Therapeutics Holdings
Employees

InVivo Therapeutics Holdings Corporation (NASDAQ:NVIV): Employee count
Aug 2023 6
Sep 2023 6
Oct 2023 6
Nov 2023 6
Dec 2023 6
Jan 2024 6
Feb 2024 6
Mar 2024 6
Apr 2024 6
May 2024 6
Jun 2024 6
Jul 2024 6

InVivo Therapeutics Holdings other data

InVivo Therapeutics Holdings
Hedge Funds Holdings Q1 2023

3.34% -18.64%
of NVIV is owned by hedge funds
11 -3
hedge funds hold NVIV stock
51.30K -254.57K
shares is hold by hedge funds
NVIV hedge funds holdings changes

InVivo Therapeutics Holdings
Insider Trading

InVivo Therapeutics Holdings Corporation (NASDAQ:NVIV): Insider trades (number of shares)
Period Buy Sel
Jun 2019 0 5229
Mar 2020 21816 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
MERRIFIELD C ANN director
 Warrant (right to buy) 3,636 $2.75 $9,999
Purchase
CHRISTOPHER RICHARD officer: CFO and .. Warrant (right to buy) 3,636 $2.75 $9,999
Purchase
CHRISTOPHER RICHARD officer: CFO and .. Common Stock 3,636 $2.75 $9,999
Purchase
TOSELLI RICHARD M. director, officer.. Warrant (right to buy) 3,636 $2.75 $9,999
Purchase
TOSELLI RICHARD M. director, officer.. Common Stock 3,636 $2.75 $9,999
Purchase
MERRIFIELD C ANN director
 Common Stock 3,636 $2.75 $9,999
Sale
TOSELLI RICHARD M. director, officer.. Common Stock 5,229 N/A N/A
Option
ROBERTS RICHARD JOHN director
 Non-qualified stock option (right to buy) 30,984 N/A N/A
Option
ROBERTS RICHARD JOHN director
 Common Stock 30,984 N/A N/A
Option
ROBERTS RICHARD JOHN director
 Non-qualified stock option (right to buy) 58,403 N/A N/A
NVIV insider trading transactions

Frequently Asked Questions (FAQ)

  • What's the price of InVivo Therapeutics Holdings stock today?

    One share of InVivo Therapeutics Holdings stock can currently be purchased for approximately $0.23.

  • When is InVivo Therapeutics Holdings's next earnings date?

    Unfortunately, InVivo Therapeutics Holdings's (NVIV) next earnings date is currently unknown.

  • Does InVivo Therapeutics Holdings pay dividends?

    No, InVivo Therapeutics Holdings does not pay dividends.

  • How much money does InVivo Therapeutics Holdings make?

    InVivo Therapeutics Holdings has a market capitalization of 995.91K.

  • What is InVivo Therapeutics Holdings's stock symbol?

    InVivo Therapeutics Holdings Corporation is traded on the NASDAQ under the ticker symbol "NVIV".

  • What is InVivo Therapeutics Holdings's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of InVivo Therapeutics Holdings?

    Shares of InVivo Therapeutics Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are InVivo Therapeutics Holdings's key executives?

    InVivo Therapeutics Holdings's management team includes the following people:

    • Dr. Richard M. Toselli Pres, Chief Executive Officer, Chief Medical Officer & Director(age: 67, pay: $832,490)
    • Mr. Richard C. Christopher Chief Financial Officer & Treasurer(age: 55, pay: $558,340)

  • How many employees does InVivo Therapeutics Holdings have?

    As Jul 2024, InVivo Therapeutics Holdings employs 6 workers.

  • When InVivo Therapeutics Holdings went public?

    InVivo Therapeutics Holdings Corporation is publicly traded company for more then 14 years since IPO on 15 Nov 2010.

  • What is InVivo Therapeutics Holdings's official website?

    The official website for InVivo Therapeutics Holdings is invivotherapeutics.com.

  • Where are InVivo Therapeutics Holdings's headquarters?

    InVivo Therapeutics Holdings is headquartered at One Kendall Square, Cambridge, MA.

  • How can i contact InVivo Therapeutics Holdings?

    InVivo Therapeutics Holdings's mailing address is One Kendall Square, Cambridge, MA and company can be reached via phone at +61 78635500.

InVivo Therapeutics Holdings company profile:

InVivo Therapeutics Holdings Corporation

invivotherapeutics.com
Exchange:

NASDAQ

Full time employees:

6

Industry:

Biotechnology

Sector:

Healthcare

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

+61 78635500
One Kendall Square
Cambridge, MA 02139

CIK: 0001292519
ISIN: US46186M6057
CUSIP: 46186M605